About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal
Noted This Week
In the phase I ANTLER trial, Caribou Biosciences’ chimeric antigen receptor (CAR) T-cell therapy, CB-010, demonstrated an overall response rate (ORR) of 100% in all five evaluable patients with relapsed/refractory B-cell non-Hodgkin lymphoma; patients had already received a median of three treatments. In addition, 80% experienced a complete response (CR) lasting up to 6 months; three patients developed grade 3 or 4 adverse events within 28 days of treatment. Caribou says that "CB-010 is the first allogeneic anti-CD19 CAR T-cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to limit premature CAR T-cell exhaustion."